Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495884 | 0.69 | ALKBH5 (0.37) | ALKBH5FTODUSP3GPR3CYP1A2 | |
| SCHEMBL4485928 | 0.66 | ALKBH5 (0.37) | ALKBH5FTODUSP3GPR3CYP1A2 | |
| SCHEMBL31069844 | 0.65 | MCL1 (0.35) | ALKBH5FTO | |
| SCHEMBL10835548 | 0.65 | MCL1 (0.35) | ALKBH5FTO | |
| SCHEMBL2671456 | 0.64 | ALKBH5 (0.36) | ALKBH5FTODUSP3GPR3CYP1A2 | |
| SCHEMBL4503588 | 0.64 | KMT2A (0.36) | — | |
| SCHEMBL4503596 | 0.64 | KMT2A (0.36) | — | |
| SCHEMBL4501446 | 0.63 | ALKBH5 (0.39) | ALKBH5FTODUSP3GPR3CYP1A2 | |
| SCHEMBL20773886 | 0.62 | ALKBH5 (0.37) | ALKBH5FTODUSP3GPR3CYP1A2 | |
| SCHEMBL11542044 | 0.62 | ALKBH5 (0.37) | ALKBH5FTODUSP3GPR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675814-A1 | COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES | Bläss, Markus (DE) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019043064-A1 | COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES | BLAESS MARKUS (DE) | 2019-03-07 | — | — | WO | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1331010-A1 | PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| US-5620973-A | CHOLINESTERASE INHIBITOR; ALZHEIMER*S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0655451-A1 | Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | ALKBH5 1849/4885FTO 3752/4885DUSP3 3366/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | ALKBH5 2013/4885FTO 2348/4885DUSP3 4177/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | ALKBH5 1601/4885FTO 2197/4885DUSP3 4072/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | ALKBH5 4808/4885FTO 4865/4885DUSP3 1560/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | ALKBH5 1721/4885FTO 2353/4885DUSP3 4086/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | ALKBH5 4808/4885FTO 4865/4885DUSP3 1560/4885 |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | UTS2R, PRSS12, CTSA | ALKBH5 4885/4885FTO 4877/4885DUSP3 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.